IP-CAT-OC-02
Laufzeit: 01.01.2006 - 31.12.2008
Kurzfassung
Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer
Laufzeit: 01.01.2006 - 31.12.2008
Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer
